Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康®, has received official approval from the China National Medical Products Administration (NMPA). This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal $(BFS)$ Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API suppliers to ensure cost-effective production and distribution.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.